Yuhan Corp
KRX:000100

Watchlist Manager
Yuhan Corp Logo
Yuhan Corp
KRX:000100
Watchlist
Price: 116 800 KRW -1.1% Market Closed
Market Cap: 8.6T KRW
Have any thoughts about
Yuhan Corp?
Write Note

Yuhan Corp
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Yuhan Corp
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Yuhan Corp
KRX:000100
Total Current Liabilities
â‚©570.5B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
10%
SK Biopharmaceuticals Co Ltd
KRX:326030
Total Current Liabilities
â‚©241.6B
CAGR 3-Years
51%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Total Current Liabilities
â‚©426.8B
CAGR 3-Years
26%
CAGR 5-Years
14%
CAGR 10-Years
4%
Hanmi Pharm Co Ltd
KRX:128940
Total Current Liabilities
â‚©623.5B
CAGR 3-Years
-2%
CAGR 5-Years
5%
CAGR 10-Years
13%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Total Current Liabilities
â‚©58.3B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
9%
C
Celltrion Pharm Inc
KOSDAQ:068760
Total Current Liabilities
â‚©237.3B
CAGR 3-Years
2%
CAGR 5-Years
12%
CAGR 10-Years
11%
No Stocks Found

Yuhan Corp
Glance View

Market Cap
8.6T KRW
Industry
Pharmaceuticals

In the bustling landscape of South Korea's pharmaceutical industry, Yuhan Corp. stands out as a venerable institution with a rich legacy and a forward-thinking approach. Founded in 1926, Yuhan has carved out a respected space in the market through its commitment to developing, manufacturing, and distributing a wide array of pharmaceutical and healthcare products. The company operates across multiple segments, focusing on prescription drugs, over-the-counter medications, and consumer health products that cater to various needs from chronic diseases to everyday health care. Yuhan’s product portfolio includes a combination of in-house innovations and collaborations with global leaders, which has allowed it to build a sustainable revenue stream and secure a substantial market share both domestically and internationally. At the core of Yuhan's business model is the strategic integration of research and development with commercial prowess. The company invests significantly in R&D to stay ahead of industry trends and meet evolving patient needs. This focus on innovation is complemented by strategic partnerships and licensing agreements with international pharmaceutical corporations, allowing Yuhan to introduce groundbreaking therapies to the Korean market. Additionally, Yuhan capitalizes on its robust distribution network, ensuring wide accessibility and penetration of its products. These efforts not only reinforce Yuhan’s position as a leader in the pharmaceutical sector but also fuel its steady financial growth, providing a reliable return on investment through a combination of direct sales and strategic partnerships.

Intrinsic Value
55 502.27 KRW
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Yuhan Corp's Total Current Liabilities?
Total Current Liabilities
570.5B KRW

Based on the financial report for Sep 30, 2024, Yuhan Corp's Total Current Liabilities amounts to 570.5B KRW.

What is Yuhan Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
10%

Over the last year, the Total Current Liabilities growth was 8%. The average annual Total Current Liabilities growth rates for Yuhan Corp have been 14% over the past three years , 13% over the past five years , and 10% over the past ten years .

Back to Top